Researchers have identified a new small-molecule drug, UNC569, as a promising therapy for pancreatic ductal adenocarcinoma (PDAC), one of the deadliest and most treatment-resistant cancers. UNC569 targets the MerTK receptor, which helps cancer cells survive and spread, triggering cancer cell death and overcoming drug resistance.
The drug works through a “two-pronged” mechanism. First, it induces DNA damage in cancer cells, blocking their ability to divide. Second, it increases toxic reactive oxygen species, activating stress pathways that prompt programmed cell death. In lab studies, UNC569 reduced PDAC cell growth, migration, and colony formation. In mouse models, it shrank tumors without significant side effects.
Importantly, UNC569 also enhances the effect of standard chemotherapy (Gemcitabine), making cancer cells more sensitive to treatment. By simultaneously attacking cancer DNA and amplifying stress signals, UNC569 offers a potential new strategy for treating pancreatic cancer and overcoming chemotherapy resistance.